Medanta Q4 FY26 Revenue Jumps 25.3% to ₹11,958 Million, PAT Up 39.7%
Global Health Limited (Medanta) reported FY2026 consolidated total income of ₹45,089 million, up 19.6% YoY. PAT grew 15.1% to ₹5,541 million. Q4 FY26 revenue was ₹11,958 million, up 25.3% YoY, with PAT at ₹1,417 million, up 39.7%. The board recommended a final dividend of 25% (₹0.50 per share).
The announcement details significant financial performance improvements, expansion plans, and a dividend payout, all of which are material factors for investors and stakeholders.
The company reported strong year-on-year growth in revenue and profit for both the quarter and the full financial year, along with an increase in bed capacity and patient volumes. The recommendation of a final dividend also contributes to the positive sentiment.
Global Health Limited (Medanta) announced its audited consolidated financial results for the quarter and full year ended March 31, 2026. For the full year FY2026, consolidated total income surged by 19.6% year-on-year to ₹45,089 million. EBITDA (excluding Noida) grew by 18.6% to ₹11,343 million, with margins at 25.7%. Profit After Tax (PAT) was ₹5,541 million, a 15.1% increase year-on-year. The company added 623 beds in FY26, including 382 at Noida, 131 at Patna, and a new 110-bed hospital in Ranchi. In-patient count increased by 16.0% and out-patient count by 18.7% year-on-year.
For the fourth quarter of FY2026 (Q4 FY2026), Medanta reported its highest ever quarterly total income of ₹11,958 million, a 25.3% increase year-on-year. EBITDA (excluding Noida) grew by 27.0% to ₹3,142 million with improved margins of 27.5%. Profit After Tax for the quarter was ₹1,417 million, a robust growth of 39.7% year-on-year, with PAT margins improving to 11.8%. During the quarter, 86 new beds were added, with 32 in Patna and 54 in Noida. In-patient count increased by 23.0% and out-patient count by 27.5% year-on-year.
The Board of Directors recommended a final dividend of 25% on the face value of ₹2 per share, amounting to ₹0.50 per share. The Noida hospital, operational since November 2025, reported revenue of ₹906 million and an EBITDA loss of ₹783 million in FY2026, with quarterly start-up losses showing a declining trend. The company plans to add approximately 500 beds across existing hospitals over the next 12 months and about 2,700 beds through five greenfield projects in the next 3-4 years.
What to do with a filing like this
Global Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Global Health Limited. Read the original for the full detail.